Syntax Bio Announces Expanded Series A and Leadership Appointments
Company raises additional capital to advance Cellgorithm™ platform, develop pancreatic beta cell therapy for type 1 diabetes and strengthen leadership
Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced an expanded Series A and new appointments to its executive leadership team, board of directors and scientific advisory board. The expansion brings Syntax Bio’s Series A to $14.4 million and total funding to over $25 million.
The expanded round builds on support from Astellas Venture Management, Illumina Ventures, DCVC Bio, Civilization Ventures, EGB Capital, Mansueto Office, and Portal Innovations, and includes new participation from Draper Associates, Allegis Capital, LongGame, Mayo Clinic, the Illinois Department of Commerce and Economic Opportunity, Illinois Ventures, Exit Fund, Sigma Group, and Walder Ventures. Proceeds will support further advancement of the company’s proprietary Cellgorithm™ platform and fund pancreatic beta cell therapy development for type 1 diabetes through pre-clinical proof-of-concept.
“We are pleased to expand our Series A with strong support from both new and existing investors,” said John Craighead, Ph.D., chief executive officer of Syntax Bio. “This financing enables us to accelerate sequential, endogenous gene activation technology, advance the first cell therapy discovered using the Cellgorithm platform and build collaborations to develop scalable regenerative medicines for serious diseases.”
